Colforsin (Forskolin, HL 362)

For research use only. Not for use in humans.

製品コードS2449 別名:Coleonol, Colforsin

Colforsin (Forskolin, HL 362)化学構造

CAS No. 66575-29-9

Colforsin (Forskolin, HL 362, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

サイズ 価格(税別)  
JPY 20200
JPY 46800
JPY 63400
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(89)

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Colforsin (Forskolin, HL 362, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  M3nzWmFxd3C2b4Ppd{BCe3OjeR?= NGfuZ5k1OMLizszN MUm0POKhcA>? NH3FRmVFVVOR Mn3jbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= NUHoeodkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480 NWXYVW1HSXCxcITvd4l{KEG|c3H5 NFnVfWc1OMLizszN NV;0eYw1PDkEoHi= M1TR[mROW09? MkSzbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  NHHpV49CeG:ydH;zbZMhSXO|YYm= MmLvOFDDqM7:TR?= NH;Gd2c1QMLiaB?= M1jkR2ROW09? MYTpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= NYXxR25TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480 NUHUSYIxSXCxcITvd4l{KEG|c3H5 M3fYe|QxyqEQvF2= NUT0Wm0yPDkEoHi= MlTwSG1UVw>? NHi5bG5qdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> NX3NTYxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
HT-29  NXXOV|hmTnWwY4Tpc44hSXO|YYm= NH;hWWw1OMLizszN NF;5bFg4KGR? NEPTTHZFVVOR MVry[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi M3L0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
SW480 NHfrWYJHfW6ldHnvckBCe3OjeR?= NXnPemVKPDEEoN88US=> NV\0Oot5PyCm NUnMVFlpTE2VTx?= NXr1TZBvemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> NHLESWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjP[I81OMLizszN MVWwMVczKGh? NEDWXWRFVVOR M3H3dIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> MmfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLvc3c1OMLizszN MlvUNE04OiCq NV7FWmFYTE2VTx?= MYLpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 M2XobVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HT-29  MlPVSpVv[3Srb36gRZN{[Xl? NWC0S5VrPDEEoN88US=> NVf0foRNPDkEoHi= NX7XVYJRTE2VTx?= M{fGboFkfGm4YYTld{BRWDKD Mn3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MnPZSpVv[3Srb36gRZN{[Xl? M1jzVlQxyqEQvF2= MYW0POKhcA>? MmjXSG1UVw>? NFvyd45i[3SrdnH0[ZMhWFB{QR?= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
C6 M3\NTmZ2dmO2aX;uJGF{e2G7 NXvXOIhWOTBizszNxsA> Mlv5NlAhdWmw MlTQbY5kemWjc3XzJINCVVBiYXPjeY12dGG2aX;u NX[xN4N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlk1OTdpPkK1NFY6PDF5PD;hQi=>
Huh-7 MWDGeY5kfGmxbjDBd5NigQ>? Mn7ONE0zOCEQvF2= MnzaNkBpyqB? MkOzdoV{fWy2czDpckBiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGNvTYnjJIV5eHKnc4Ppc44h[XRidHjlJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wy| MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUizOEc,OjVzMEm4N|Q9N2F-
THP-1  MY\GeY5kfGmxbjDBd5NigQ>? Mn7sNU8yOCEQvF2= NFvhN|EzyqCq NITmTVlFVVORwrC= NUe3b|dGe3WycILld5NmeyCPQ2CtNUBxem:mdXP0bY9vyqB? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3NEi4Nkc,OjVzNUS4PFI9N2F-
BeWo  NGHINoNHfW6ldHnvckBCe3OjeR?= NFPieo8zOCEEtV2= NXj6SlJzPDhiaB?= NVHnWJBDTE2VT9Mg MnP3bY5lfWOnczDj[YxtKG[3c3nvci=> NWHuTVI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPFQ1PzdpPkK1NVg1PDd5PD;hQi=>
ventricular cardiomyocytes  NUTBUnpwTnWwY4Tpc44hSXO|YYm= NISzcGQxNjBzLUGwJO69VQ>? MXrleo9s\XNiYX6gbY5wfHKxcHnjJJJme3CxboPlJFEzOMLzMUWlJIFjd3[nIHLhd4FtKHerdHigZY4hTUN3MNMgc4YhOi5{INM1US=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyM{GxN{c,OjV{MEOxNVM9N2F-
ventricular cardiomyocytes  M{m4b2Z2dmO2aX;uJGF{e2G7 M2LWVlAvODFvMUCg{txO M2LyV4lv[3KnYYPld{Ah[0GPUDDhZ4N2dXWuYYTpc44> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyM{GxN{c,OjV{MEOxNVM9N2F-
MIN6  MoPKSpVv[3Srb36gRZN{[Xl? M1z0OFExKM7:TdMg MV[zJIg> NEjjdGdqdmO{ZXHz[ZMhTDNibWLORUBmgHC{ZYPzbY9v NIW1[GY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0NVEzPCd-MkWyOFEyOjR:L3G+
L6 NGfob3dHfW6ldHnvckBCe3OjeR?= MU[0NEDDvU1? NGfnR2ozPCCq NXfleFFDcW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v NXrCTmNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFc2PTBpPkK1NlQ4PTVyPD;hQi=>
HEK‐CFTR NEW3eVZHfW6ldHnvckBCe3OjeR?= Mn7QNwKBmzVywrFOwG0> NHPvVVYxNTF{IH3pci=> NHjNU|hFVVORwrC= NXz5XJl3cW6mdXPld{BiKGSxc3ZihLBl\XCnbnTlcpQhcW:maXTlJIVn\my3eNMg M{\JRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zNlA4Lz5{NUK2N|IxPzxxYU6=
SK-N-SH NEjwPHpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYnnbYhSOTBizszNxsA> NHzrWFQ1QCCq MlP4[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  MnXpSpVv[3Srb36gRZN{[Xl? NXT5RXM2OTBizszNxsA> MonxNVAwOzBxNkCgcYlv M{T4eIlv[3KnYYPld{Bt\X[nbIOgc4YheC4Qsj3jZZRmdmmwIDjz[ZI3PzVrIHHu[EBqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDwMe6zNWOjdHXubY4hMHOnck[3OUkhcW5iKIDldokqdnWlbHXhdkBz\Werb37z Mnf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  NH3CZnJHfW6ldHnvckBCe3OjeR?= M3:1XVExKM7:TdMg M{XWbVMxKG2rbh?= M1vrdIlv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJO6zNWOjdHXubY4hMHOnck[3OUktKHBvR2PLN:6zKCi|ZYK5LUBidmRiY3;uZ49ucXSjboSgbIlocGW{IHzleoVteyCxZjDhZ5RqfmVuIIXudIhwe3Cqb4L5cIF1\WRuIN8yMYNifGWwaX6= Mn7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  M3nQVmZ2dmO2aX;uJGF{e2G7 MVuxNEDPxE4EoB?= NUXB[2gzOjRiaB?= M2C3Z4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBkgWOuaX6gSFE> NYjnT246RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
SK-N-AS  MkLBSpVv[3Srb36gRZN{[Xl? MmDZNVAh|ryPwrC= M3\2T|I1KGh? M4j2dYlv[3KnYYPld{B1cGViY1HNVEBt\X[nbIRCpC=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  NH;oeGlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUSxNEDPxE4EoB?= NXPPb2VTOjRxNEigbC=> M2DSUIVvcGGwY3XzJJRqdWVvZHXw[Y5l\W62bImgZ4VtdHWuYYKgeoli[mmuaYT5xsA> NG\pV|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
granulosa cells M1PNe2Z2dmO2aX;uJGF{e2G7 MVOxNEDPxE1? NF32TXAzPCCq Mkj1bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUlfTNkBxem:vb4TldkBi[3Srdnn0fS=> NIfJSYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVExPSd-MkWzN|kyODV:L3G+
granulosa cells NGrXc4xHfW6ldHnvckBCe3OjeR?= MVWxNEDPxE1? M{niW|I1KGh? MoXnbY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[gSG5CN3C{b4TlbY4h[2:vcHzlfC=> M3jzVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
granulosa cells M4T6bmZ2dmO2aX;uJGF{e2G7 NV\oRYE6OTBizszN MkfhNVIwOjRiaB?= NX;JVGVNcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdoVxd3K2ZYKgZYN1cX[rdImg[o9zKHSqZTDsc45o\XO2IH\yZYdu\W62IDlijLI5PTRxK{G4VmdUOi6OVVOp MnG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{mxNFUoRjJ3M{O5NVA2RC:jPh?=
granulosa cells NXX5bG11TnWwY4Tpc44hSXO|YYm= NFr4dIMyOCEQvF2= NFvrcJQyOi9{NDDo MmXTbY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= NE\rWFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVExPSd-MkWzN|kyODV:L3G+
BeWo  M{n2V2Z2dmO2aX;uJGF{e2G7 Mm\QNlDDqML3TR?= NVrPNZJzPDkEoHlCpC=> MVTEUXNQyqB? NVrMTpI6\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXygc4YhT0OPLUG= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MkK2NEc,OjV|NkKyOlA9N2F-
BeWo  Mm\ESpVv[3Srb36gRZN{[Xl? NGW2T44zOMLiwsXN M2\B[VQ5yqCqwrC= NV75fJlVTE2VT9Mg Mkjy[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gWG1GVUZzNh?= NHvhe3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NlI3OCd-MkWzOlIzPjB:L3G+
BeWo  MUXGeY5kfGmxbjDBd5NigQ>? NFHiW5IzOMLiwsXN NXPHZodMPDkEoHlCpC=> MXTEUXNQyqB? MUXpcoNz\WG|ZYOgeIhmKGKndHGtbGNIKHKnbHXhd4U> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MkK2NEc,OjV|NkKyOlA9N2F-
EM1  MWnGeY5kfGmxbjDBd5NigQ>? NUj5TG05OTYkgJtOwG0> MVG0PEBp NEn4NYtz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBNUUcEoH;yxsBRXEeVMtMgbY7DqEODTGKtJI9zyqCHUFHDNk1{cWynbnPl[EBGVTFiY3XscJPDqA>? MkPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|N{i2OlEoRjJ3M{e4OlYyRC:jPh?=
Primary bovine chondrocytes NYLDfXFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPae3A2|ryP M2XUWFQ5KGh? MUDy[ZZmenOnczD0bIUhcW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3Xs[YNwgGmkIH;uJJBzd2yrZnXyZZRqd25iaX6g[5Jwf3SqIIDsZZRmKGOqb37kdo9kgXSncx?= NXLp[YpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFYxOTZpPkK1OFA3ODF4PD;hQi=>
RBMECs MWLGeY5kfGmxbjDBd5NigQ>? NF;0dmY2yqEQvF2= NFP1[G4yKGh? MXzicI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg NH7nT3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NILQT2lHfW6ldHnvckBCe3OjeR?= NF60dpk2yqEQvF2= MUWxJIg> NVzZXYlN[myxY3vzJJRp\SCHTVHQMWlKNWmwZIXj[YQh[2ijbnflJIlvKE2OQzDwbI9{eGixconsZZRqd25? MoDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs MVTGeY5kfGmxbjDBd5NigQ>? Mo\UOeKh|ryP NGm2NmkyKGh? MVjy[ZZmenOnczD0bIUh[2ijbnfld{BqdiCcTz2xJIRqe3S{aXL1eIlwdiC|ZXXuJJdqfGhiRV3BVE1KUSC2cnXheI1mdnR? NWjmPJJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs MYDGeY5kfGmxbjDBd5NigQ>? MWK1xsDPxE1? MUmxJIg> MnTjbY5pcWKrdIOgeIhmKGSnY4LlZZNm\CCxZjDhcY92dnRib3[gXm8uOSCrbjDNSpMhcW6mdXPl[EBjgSCHTVHQMWlK NFu4cWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NXX0fIJiTnWwY4Tpc44hSXO|YYm= MknjOeKh|ryP NE[xWI8yKGh? MXrwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? M{mxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs M2rufmZ2dmO2aX;uJGF{e2G7 M4HlU|XDqM7:TR?= NF7SSY8yKGh? MVLwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> MnnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs M3;XZmZ2dmO2aX;uJGF{e2G7 MnTNOeKh|ryP M33se|EhcA>? M3LhXoJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ NXfMcVZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs MVfGeY5kfGmxbjDBd5NigQ>? NEn3fYoxNjB3L{CuOU82KM7:TR?= M1\Vb|AvOjViaB?= NWfpNFBmcW6lcnXhd4V{KGODTWCgZ49v[2WwdILheIlwdg>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
ThGCs  NHHnb21HfW6ldHnvckBCe3OjeR?= M4r3[FEx6oDMzszN Mn;xN{Bp M{X0fYlvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiSELPNkBwdiCHRF6yJI1TVkF? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR|M{CyO{c,OjV2M{OwNlc9N2F-
ThGCs  M2jGTWZ2dmO2aX;uJGF{e2G7 NVr1OmR7OTEkgJtOwG0> M3qxNVTjiIqq NWDESVlxcW6lcnXhd4V{KEOxQ3yyMYlv\HWlZXSgSWRPOsLiZ3Xu[UBmgHC{ZYPzbY9v MnzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{OwNlcoRjJ3NEOzNFI4RC:jPh?=
ThGCs  MnzrSpVv[3Srb36gRZN{[Xl? M1zYeVEx6oDMzszN M{HRVVTjiIqq MmL1ZZVodWWwdIOgTGlHOUFibHX2[Yx{KHSqYYSge4Vz\SC|dHnteYxifGWmIHL5JGNwS2x{ NEfS[|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzN|AzPyd-MkW0N|MxOjd:L3G+
LNCaP  Mn7PSpVv[3Srb36gRZN{[Xl? MlL4NVDDqM7:TR?= NWjuSFBUOTJiaNMg M{PoT2ROW09? NFL1T49qdmS3Y3XzJIEh\HKjbXH0bYMhcW6lcnXhd4Uhd2ZiQ2LFRlEh[WO2aY\peJk> NVPycpBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OFgxQTlpPkK1OVQ5ODl7PD;hQi=>
BeWo NHHzcFZHfW6ldHnvckBCe3OjeR?= M{n2flIxyqEEtV2= NHvkXGI1QMLiaB?= MV3EUXNQ MoWxbY5kemWjc3XzJJRp\SCjZHjld4lwdiCxZjDUTHAuOSCvb37vZ5l1\XN? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4Nke0NEc,OjV3Nk[3OFA9N2F-
BeWo NUPRXJdRTnWwY4Tpc44hSXO|YYm= NV3mXnhJOjEEoNM1US=> MnO5OFjDqGh? MVfEUXNQ NVPTZ3JYcW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> NVH0RmkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlY4PDBpPkK1OVY3PzRyPD;hQi=>
OCI-Ly18  NGL4[GxHfW6ldHnvckBCe3OjeR?= MWC0NOKh|ryP NETaOpQyyqCqwrC= NXK2bFNwTE2VTx?= MUXpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkKyNEc,OjV3N{[yNlA9N2F-
OCI-Ly1  NUTXOIlJTnWwY4Tpc44hSXO|YYm= MmDGOFDDqM7:TR?= MVixxsBpyqB? MVHEUXNQ MkXObY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkKyNEc,OjV3N{[yNlA9N2F-
3T3-L1 NV36eFA3TnWwY4Tpc44hSXO|YYm= MnXDNk42NzVizszN MWqyOEBpyqB? MUXzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCDVFfMJJBzd3SnaX6g[ZhxemW|c3nvckBifCCjbHyg[I9{\XNidHXzeIVl MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEW5O{c,OjV3OUC1PVc9N2F-
HEK293  NFHGbYNHfW6ldHnvckBCe3OjeR?= M1LP[FXjiIoEtV2= NYLrbHRnOzBibXnu MkG3bY5kemWjc3XzJINCVVBibHX2[Yx{ NV7BeYdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVE6ODhpPkK1OVkyQTB6PD;hQi=>
hADSCs NGnSSnhHfW6ldHnvckBCe3OjeR?= Mk\FOgKBkcL3TR?= NWTJ[25MOzBibXnu MVzpcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MUmwPEc,OjV3OUG5NFg9N2F-
SH-SY5Y  NYfNO403TnWwY4Tpc44hSXO|YYm= M3vBXFExyqEQvF2= M3LIUVHDqGkEoB?= MVvpcoNz\WG|ZYOgRWdEOSCvUl7BJIxmfmWu NXPU[mY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
SH-SY5Y  MVXGeY5kfGmxbjDBd5NigQ>? Mk\KNVDDqM7:TR?= MXexxsBpyqB? MU\pcoNz\WG|ZYOgUHVEKGGldHn2bZR6 MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7N{SzN{c,OjV3OUe0N|M9N2F-
UACC-647  NWfMcJZuTnWwY4Tpc44hSXO|YYm= NFvzeI4yOMLizszN M2r6[FE2KG2rbh?= MmnlSG1UVw>? NHTMTlZqdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB? M{X1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNFI2Lz5{NUewN|AzPTxxYU6=
UACC-647  NF3HNYZHfW6ldHnvckBCe3OjeR?= NYjhWVFUOTEEoN88US=> NHy5Vm0yPSCvaX6= NX[3OXp3TE2VTx?= Mn7mbY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> NVPOPFZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMxOjVpPkK1O|A{ODJ3PD;hQi=>
UACC-647  MVvGeY5kfGmxbjDBd5NigQ>? MkjJSG1UVw>? MmPRcIVi\HNidH:gZUBzcXOnIHnuJINCVVBibHX2[Yx{KCiHQ{WwxsA:yqB{MD6zPeKh|ryPKR?= NF3EbmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN|AzPSd-MkW3NFMxOjV:L3G+
SC MofZSpVv[3Srb36gRZN{[Xl? Mk\0NE42KM7:TR?= NVSwUINiPzJiaB?= M3rPZolv[3KnYYPld{Bjd3SqIFvyc5guOjBiYX7kJG8yKGW6cILld5Nqd25iaX6gZZhwdi2{ZXzheIVlKFOFczDieZQhd26ueTDLdo95NTJywrC= NYHwOIdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFU5PzRpPkK1O|A2QDd2PD;hQi=>
SC NWP0WVF3TnWwY4Tpc44hSXO|YYm= M1;SZVAvPSEQvF2= NEj4coozPCCq MlTVcYlucWOtczD0bIUh\W[oZXP0JI9nKGODTWCgZY5idG:pczDvckBQOSCjbnSgUWJRKGW6cILld5Nqd25? NGfoNpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewOVg4PCd-MkW3NFU5PzR:L3G+
oocytes MnzFSpVv[3Srb36gRZN{[Xl? MmW5OUDPxE1? NEnFVJMzPCCq NYLjZoQ5[XS2ZX71ZZRmeyC{aD3pcpN2dGmwIHHjeIlwdiCxbjDvc4N6fGViR2\CSEB{cWewaX\pZ4FvfGy7wrC= MnT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEe4OVQoRjJ3N{C3PFU1RC:jPh?=
BeWo Mo\xSpVv[3Srb36gRZN{[Xl? NFX4VGMyOOLCit88UeKh MVi3NkBp MkDxSG1UVw>? NH\YOHFu\WSrYYTld{BD\VexIHPlcIwh\GmoZnXy[Y51cWG2aX;u NILWNXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexN|QzPSd-MkW3NVM1OjV:L3G+
GH3 NVPofow4TnWwY4Tpc44hSXO|YYm= MV:xxsDPxE1? MofJOk1p M2W5SIlv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u NYr4RXBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlcxOThpPkK1O|I4ODF6PD;hQi=>
GH3 M1HveGZ2dmO2aX;uJGF{e2G7 M{TuOVHDqM7:TR?= NG\mc|g3NWh? M3rn[IF1fGWwdXH0[ZMhfGinIHPvdpJmdGG2aX;uJIJmfHenZX6gVHJNKGGwZDDCcYFtOSCneIDy[ZN{cW:w NEfGToI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO|AyQCd-MkW3NlcxOTh:L3G+
PC12 M1:2b2Z2dmO2aX;uJGF{e2G7 NVj6dpl6OjYEoN88US=> NYT2UJV1PDhiaB?= M2foNIFkfGm4YYTld{BkSU2S NH7BTnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2PVMxPSd-MkW3Olk{ODV:L3G+
BAECs NX;kc4hqTnWwY4Tpc44hSXO|YYm= NWHo[Y15OjVizszN NHjBW4IzPCCq NWTqdZg6\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=> NUPvWFZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVg5OjZpPkK1O|k5QDJ4PD;hQi=>
GLUTag  M{mxU2Z2dmO2aX;uJGF{e2G7 NGXEeVcyOOLCidM1US=> MkP4OEBp NYn2W5hJcW6lcnXhd4V{KHSqZTDwR3JGSiCuZY\lcJMhf2m2aDD0bIUhUUKPWB?= Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{K2N|EoRjJ3OEOyOlMyRC:jPh?=
GLUTag  Ml3tSpVv[3Srb36gRZN{[Xl? NVq2SZBIOTEkgJpCuW0> NXyxcWV2OC9{L{SgbC=> NE\Ue4t{fGmvdXzheIV{KEeOUD2xJJNm[3KndHnvckBkd3S{ZXH0[YQhf2m2aDDJRm1Z M17DU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
PBMC MXvGeY5kfGmxbjDBd5NigQ>? NHjC[VI2OMLizszN M32wTlI1yqCqwrC= MWTpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG NGexUFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OlA4QSd-MkW4OlYxPzl:L3G+
H295R  NWfaVYsxTnWwY4Tpc44hSXO|YYm= Mo\CNVDDqM7:TR?= MnrmOFjDqGh? MYrpcoNz\WG|ZYOgd5Rmem:rZDDt[ZRi[m:uaYTld{BqdiC2aHWgZY5lem:pZX6sJI1qdmW{YXzvMUBidmRiZ3z1Z49kd3K2aXPvbYQheGG2aIfhfZM> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUW1Okc,OjV6Nkm1OVY9N2F-
3T3-L1 preadipocytes NIX5NXZHfW6ldHnvckBCe3OjeR?= M3[3dVExKM7:TdMg MYKxNkBp NWLZcGpKcW6mdXPld{BEWkWEIIDoc5NxcG:{eXzheIlwdiCjbnSgR{9GSlEQsjDlfJBz\XO|aX;u MoPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MkiwOVgoRjJ3OUK4NFU5RC:jPh?=
PCCL3 MnrqSpVv[3Srb36gRZN{[Xl? MonuNVAhyrWP MnHONlQhcA>? MYflcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? NGLoVJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NFk2Pid-MkW5OlA6PTZ:L3G+
SCG MVzGeY5kfGmxbjDBd5NigQ>? NGmxe5oyODBizszNxsA> MlTXSG1UVw>? MYLy[YR2[2W|IITo[UBmgGOrdHHibYxqfHlib3[gV2NIKG6ndYLvcpM> NGLDbJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NlE{Oid-MkW5OlIyOzJ:L3G+
HEK-293 M2jFOmZ2dmO2aX;uJGF{e2G7 MlvNN|Uh|ryPwrC= M4j6WWROW09? MX\pcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 M4L4NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[yNVMzLz5{NUm2NlE{OjxxYU6=
SCG NH\jWHhHfW6ldHnvckBCe3OjeR?= MYSyNEDPxE4EoB?= M{DrN2ROW09? MWHy[ZZmenOrYnz5JJN2eHC{ZYPz[ZMhUUuYIIfpeIgh[SCLQ{WwJI9nKDJ2LkSg{txO NF;6epc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NlE{Oid-MkW5OlIyOzJ:L3G+
PC-3 M1S0WmNmdGxiVnnhZoltcXS7IFHzd4F6 NVKwWGNqPDBiwsXN NFTvWFIzPC92OD:3NkBp NF\3SJlFVVOR NVy5eZN6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm= MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkO4N|YoRjJ4MEKzPFM3RC:jPh?=
PC-3 MormSpVv[3Srb36gRZN{[Xl? M3K1T|QxKML3TR?= MnHpNkBp M2fIbmROW09? NGTlOI5t\WGmczD0c{BRWDKDIHHjeIl3[XSrb36= NF7Wd5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g{Pid-Mk[wNlM5OzZ:L3G+
SH-SY5Y NYHvTnRXTnWwY4Tpc44hSXO|YYm= M37aTlMxKM7:TR?= NHnrboM{OCCvaX6= MXTEUXNQ M1\nNJNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> MlXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkWxN|coRjJ4MEK1NVM4RC:jPh?=
EndoC-βH1 Mlq2SpVv[3Srb36gRZN{[Xl? NHSzRpI2yqEQvF2= M3GxNVEhcA>? MX\s[YFleyC2bzDhJJN1em:wZzDjRW1RKGmwY4LlZZNm MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{OEW2Nkc,OjZyMki1OlI9N2F-
EndoC-βH1 M2TqeGZ2dmO2aX;uJGF{e2G7 NUPpXGVTPcLizszN NUSycG1[OSCq M1fqbZBwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> NF7MXG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyPFU3Oid-Mk[wNlg2PjJ:L3G+
RBMECs M2DjSGZ2dmO2aX;uJGF{e2G7 MVe1xsDPxE1? NW\3VmRGOSCq MWHpcohq[mm2czDFUWFRNUmLLXnu[JVk\WRiaX7hZ5RqfmG2aX;uJI9nKFKjcEJCpC=> M1zKVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES0OlY{Lz5{NkC0OFY3OzxxYU6=
AML-12  NX\pS5lETnWwY4Tpc44hSXO|YYm= M2rJblIxKM7:TR?= MWOzJIg> NVnwd2RYcW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25ib3[gR3JVSzMEoB?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OEm4OUc,OjZyNEi5PFU9N2F-
AML-12  M1K0cmZ2dmO2aX;uJGF{e2G7 MlvENlAh|ryP NVPic3hVOyCq MnXxeZAuemWpdXzheIV{yqCSZ3OxZUzDqFCncHPrMEBidmUEoFe2dIPDqG2UTlGgcIV3\Wy| MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  MWTGeY5kfGmxbjDBd5NigQ>? MnrvNlAh|ryP NF7NflYyNThiaB?= NIHMNGVqdmO{ZXHz[ZMh\2y3Y3;z[UBxem:mdXP0bY9v NInWXlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PFk5PSd-Mk[wOFg6QDV:L3G+
AML-12  MlvVSpVv[3Srb36gRZN{[Xl? NIPO[4QzOCEQvF2= NEK0dIo{KGh? MnjOeZBz\We3bHH0[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcJMh[XRiVHjyMVQyOSCjbnSgV4VzNTR7Mx?= NWX5bHU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFg6QDVpPkK2NFQ5QTh3PD;hQi=>
Caco-2  NEfXVYpHfW6ldHnvckBCe3OjeR?= NIjHSXcxNjFxMT:xNEDPxE1? Mn3CNlQhcA>? M3TjbYlv[3KnYYPld{BOWlB{IIDyc5RmcW5ibHX2[Yw> NH3CRXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PVExOid-Mk[wOFkyODJ:L3G+
Caco-2  NH7GO3hHfW6ldHnvckBCe3OjeR?= MUKwMlEwOS9zMDFOwG0> MUmyNOKhdWmw M{LKcYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IHPBUXAhdGW4ZXzz MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OUGwNkc,OjZyNEmxNFI9N2F-
bovine oocytes MlXRSpVv[3Srb36gRZN{[Xl? M3nmXlExOMLizszN NYnGTVFHOTMEoHi= NHX6foxqdmirYnn0d{B1cGViZX\m[YN1KG:oIF7QVGEh[W6mL3;yJG5RWENidH:gd5RqdXWuYYTlJJJme3WvcITpc44hd2ZibXXpc5Nqew>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3MU[xNUc,OjZyNUG2NVE9N2F-
BeWo  NV7mRVhXTnWwY4Tpc44hSXO|YYm= M3;MdVI26oDLzszN MWeyOE81QC95MjDo NULHN3F3dGWjZIOgeI8h[W5iaX7jdoVie2ViaX6geIhmKGW6cILld5Nqd25ib3[gc5Rp\XJiZoXzbY9vKG2jcnvldpM> NVXWS2hZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVM2PDlpPkK2NFU{PTR7PD;hQi=>
Spinal cords  M1ThWWZ2dmO2aX;uJGF{e2G7 MUmxxsDPxE1? NGHPT2E{OCCvaX6= MWfzeIlufWyjdHXzJINCVVBibHX2[Yx{ NInSWoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOlkzPid-Mk[xNlY6OjZ:L3G+
MDCK  NFTTOVRHfW6ldHnvckBCe3OjeR?= NEXXN3EyOCEEtV2= MnSwNlQhcA>? NHqxTlRFVVOR NWLqc4dUcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDlfJBz\XO|aX;uJI9nKE[QIHPheZNm\CCkeTDUS2Yu|rJz NV\XZZBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
MDCK  MWnGeY5kfGmxbjDBd5NigQ>? MnzrNVAhyrWP M2riUFI1KGh? M{jBZmROW09? MYH1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBVT0ZvzsKxJIFv\CCFVFfGxsA> NVrwO|VmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
RPMI 8226 NWXaT2QxS2WubDDWbYFjcWyrdImgRZN{[Xl? MYqwMVExOCEQvF2= MnPQO|LjiImq MmHibY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= MlLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
H929 M1n4ZWNmdGxiVnnhZoltcXS7IFHzd4F6 NEmxRYUxNTFyMDFOwG0> M3PyU|cz6oDLaB?= MUPpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= M{TB[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
U266 M1izbmNmdGxiVnnhZoltcXS7IFHzd4F6 M{[2[|AuOTByIN88US=> NH6zRpo4OuLCiXi= NVrGcos3cW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> M{TUU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
OPM-2 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmLJNE0yODBizszN NXrtc29oPzMkgJno NGLJSW1qdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4i3SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
INA-6 MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{\nR|AuOTByIN88US=> MlPYO|LjiImq MVPpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= M3jEd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
RBMECs  NVO5Zpg1TnWwY4Tpc44hSXO|YYm= NXzmb|NTPcLizszN NFizflQyyqCq M3rkOIJtd2OtczD0bIUhWmGlMTDpcoFkfGm4YYTpc44hcW6mdXPl[EBjgSCHTVHQMWlK M4HQS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{W4NFM6Lz5{NkO1PFA{QTxxYU6=
Mo-DCs MWrGeY5kfGmxbjDBd5NigQ>? MnXGOVAh|ryP NYD6bmtKOjUkgJno MXnwdo9ud3SnczDJUE0zOyCycn;keYN1cW:wIHnuJJRp\SC|dYDldo5ifGGwdDDv[kB7gW2xc3HuJJN1cW23bHH0[YQhVW9vRFPzxsA> NWjTc2xxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVI6PDhpPkK2OFEzQTR6PD;hQi=>
HEK293 NI\ITHZHfW6ldHnvckBCe3OjeR?= NH3IfnoyOCEQvF2= MVq2JIg> NYmwfYVCcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR|NUS5PEc,OjZ2M{W0PVg9N2F-
ASK MWnGeY5kfGmxbjDhd5NigQ>? MVexJIhz MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OU[0NUc,Ojh2OU[0NVww[T5?
Vero E6 MlLyRY51cX[rcnHsJIF{e2G7 MoL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NkO1N|koRjF5Nk[zOVM6RC:jPh?=
epithelial cells M4LKbmZ2dmO2aX;uJIF{e2G7 M2S3d|EhfU1? NHXWT5I1NCB4LDDhcoQhQCCmYYnz MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
HepG2 (DPX-2) Ml\aSpVv[3Srb36gZZN{[Xl? MX:yOEBpenN? MkDmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HepG2 MkDiSpVv[3Srb36gZZN{[Xl? MlvnNlQhcHK| MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HepG2 (DPX-2) NEmxcI5HfW6ldHnvckBie3OjeR?= NFfQUYczPCCqcoO= NHeyXVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEm2OlA1Oyd-MkC5OlYxPDN:L3G+
HEK293T NYjiVGR3TnWwY4Tpc44h[XO|YYm= MlrGNVAhfU1? NWHXRWJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFc{OjVpPkK0N|g4OzJ3PD;hQi=>
HEK293 MkDGSpVv[3Srb36gZZN{[Xl? NH\yV2MyOCC3TR?= NEDHN5EyPiCqcoO= MoXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2M{W1NVIoRjJ4NEO1OVEzRC:jPh?=
MCF7 MkjLR5l1d3SxeHnjbZR6KGG|c3H5 NEnjR4M1QCCqcoO= MnLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{i2PVIoRjJ6OEO4OlkzRC:jPh?=
HEK293 M3nDb2Z2dmO2aX;uJIF{e2G7 NHPJZ3g{OCCvaX7z MlXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xO|YoRjNyMEC2NVc3RC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol ''37 mg/mL ''37

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
別名 Coleonol, Colforsin
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT02807415 Completed Drug: Lumacaftor plus Ivacaftor Cystic Fibrosis Hannover Medical School|Heidelberg University|University of Giessen June 1 2016 --
NCT02586883 Completed Other: bronchial ddp test Idiopathic Dilation of the Bronchi Assistance Publique - Hôpitaux de Paris March 29 2016 Not Applicable
NCT03652090 Completed Procedure: cell sampling Cystic Fibrosis Institut National de la Santé Et de la Recherche Médicale France|ABCF2 September 1 2010 --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Colforsin (Forskolin, HL 362)を買う | Colforsin (Forskolin, HL 362) ic50 | Colforsin (Forskolin, HL 362)供給者 | Colforsin (Forskolin, HL 362)を購入する | Colforsin (Forskolin, HL 362)費用 | Colforsin (Forskolin, HL 362)生産者 | オーダーColforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)化学構造 | Colforsin (Forskolin, HL 362)分子量 | Colforsin (Forskolin, HL 362)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID